Try our Advanced Search for more refined results

Deals Rumor Mill: Amgen, Wal-Mart, Cinven

By Karlee Weinmann (August 7, 2013, 4:30 PM EDT) -- Biotech giant Amgen Inc. is closing in on a much-anticipated $9.5 billion buyout of cancer treatment provider Onyx Pharmaceuticals Inc. and could announce finalized terms within the next week, according to a Wednesday report from Reuters. The dealmaking scene has buzzed with speculation over whether — and when — the two could hammer out a sale agreement, sure to be one of the largest the drugmaking sector has seen this year. Onyx spurned a separate bid from Amgen in late June, but has suggested it would go for a bid around $130 per share, the price Amgen is willing to pay....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!